Introduction

This report summarizes the data reported within the specified period for the Quarter 3, 2017, anti-Toxoplasma Antibody in dried blood spots (DBS) PT Program. It is distributed to all participants, state laboratory directors, and program colleagues by request. The tables within this report provide certification profiles for the distributed specimens, statistical analysis of the quantitative data, and frequency distribution summaries for expected interpretations. An evaluation of your laboratory’s data is attached to this summary.

Certification of PT Specimens

This DBS panel was prepared from serum samples positive for Toxoplasma IgG and IgM purchased from SeraCare (Medford, Massachusetts) and from human serum positive for exposure to *Toxoplasma gondii* from a CDC specimen bank. All serum samples were mixed with washed red blood cells and the final hematocrit was adjusted to 50%. Table 1 provides the anti-Toxoplasma IgM expected values based on the NSQAP assayed values determined for each specimen by fluoroimmunoassay. Expected Clinical Assessments were based on a cutoff of 10 EIU/mL.

Table 1. NSQAP anti- *Toxoplasma* IgM Expected Values

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Expected Value (EIU/mL)</th>
<th>SD</th>
<th>Clinical Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>317T1</td>
<td>0.0</td>
<td>3.1</td>
<td>1</td>
</tr>
<tr>
<td>317T2</td>
<td>0.0</td>
<td>3.3</td>
<td>1</td>
</tr>
<tr>
<td>317T3</td>
<td>33.8</td>
<td>5.8</td>
<td>2</td>
</tr>
<tr>
<td>317T4</td>
<td>212.5</td>
<td>20.8</td>
<td>2</td>
</tr>
<tr>
<td>317T5</td>
<td>0.0</td>
<td>3.2</td>
<td>1</td>
</tr>
</tbody>
</table>

1 = *Toxoplasma* antibody non-reactive  2 = *Toxoplasma* antibody reactive

Distribution of PT Specimens

On July 10, 2017 a panel of five unknown DBS specimens was distributed to three laboratories in the United States and 14 laboratories in other countries.
**Participant Results**

- **Quantitative Screening Results**

We processed data from eight participants. Laboratories were asked to report IgM screening results in Absorbance (OD) or other units. Four laboratories reported using an enzyme immunoassay method (OD), two reported using an ELISA (EIU/mL), one used a fluorometric enzyme immunoassay (EIU/mL) to detect IgM, and one lab reported IgM and IgG results using a chemiluminescent immunoassay (CLIA). Overall statistics and cutoff information for the various immunoassay methods are summarized in Table 2.

<table>
<thead>
<tr>
<th>Method/ Antibody</th>
<th>Specimen</th>
<th>N</th>
<th>Mean</th>
<th>SD</th>
<th>Mean Reported Cutoffs</th>
<th>Range Reported Cutoffs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enzyme Immunoassay IgM (OD*)</td>
<td>317T1</td>
<td>4</td>
<td>0.007</td>
<td>0.004</td>
<td>0.197</td>
<td>0.100—0.400</td>
</tr>
<tr>
<td></td>
<td>317T2</td>
<td>4</td>
<td>0.013</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>317T3</td>
<td>4</td>
<td>0.013</td>
<td>0.123</td>
<td>0.402</td>
<td>0.148</td>
</tr>
<tr>
<td></td>
<td>317T4</td>
<td>4</td>
<td>0.402</td>
<td>0.148</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>317T5</td>
<td>4</td>
<td>0.017</td>
<td>0.020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enzyme Immunoassay IgM (EIU/mL**)</td>
<td>317T1</td>
<td>2</td>
<td>29.7</td>
<td>2.8</td>
<td>120</td>
<td>80-120</td>
</tr>
<tr>
<td></td>
<td>317T2</td>
<td>2</td>
<td>48.6</td>
<td>10.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>317T3</td>
<td>2</td>
<td>337.9</td>
<td>1.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>317T4</td>
<td>2</td>
<td>310.6</td>
<td>32.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>317T5</td>
<td>2</td>
<td>88.7</td>
<td>1.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

OD = Absorbance Units  **EIU/mL = Enzyme International Units/mL serum

- **Quantitative Confirmatory Results**

Participants were asked to confirm specimens that screened above their cutoff for sorting test results that were Toxoplasma-antibody reactive from those that were Toxoplasma-antibody non-reactive. Two laboratories provided confirmatory results using an EIA for IgG.
Qualitative Clinical Assessments

Qualitative assessments may differ by participant because of specific assessment practices. Laboratory results were evaluated on the basis of the final assessments provided (screening only or confirmatory results). The frequency distribution of participant screening and confirmatory Clinical Assessments for both IgM and IgG are shown in Table 3.

Table 3. Frequency Distribution of Reported Clinical Assessments—All Methods

<table>
<thead>
<tr>
<th>Type of Testing</th>
<th>Specimen</th>
<th>Toxoplasma antibody Non-reactive</th>
<th>Toxoplasma antibody Reactive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening</td>
<td>317T1</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>317T2</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>317T3*</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>317T4</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>317T5</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Confirmatory</td>
<td>317T1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>317T2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>317T3*</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>317T4</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>317T5</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

* Specimen 317T3 was not evaluated due to lack of 80% participant consensus.

Evaluations

Overall, participants reported one False-negative and no False-positive final Clinical Assessments.
Future Shipments

The Newborn Screening Quality Assurance Program will ship next quarter’s TOXOPT specimens on October 2, 2017.

The content of this report may also be located on our website at: http://www.cdc.gov/labstandards/nsqap_reports.html
This *NEWBORN SCREENING QUALITY ASSURANCE PROGRAM* report is an internal publication distributed to program participants and selected program colleagues. The laboratory quality assurance program is a project cosponsored by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories.

**CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) ATLANTA, GA 30341**

**Acting Director**
Brenda Fitzgerald, M.D.

**Director**
National Center for Environmental Health
Patrick Breysse, Ph.D.

**Director**
Division of Laboratory Sciences
James L. Pirkle, M.D., Ph.D.

**Chief**
Newborn Screening and Molecular Biology Branch
Carla Cuthbert, Ph.D.

**Contributors:**
- Carter Asef
- John Bernstein
- Quan Bui
- Paul Dantonio
- Sharon Flores
- Elizabeth M. Hall
- Christopher Haynes, Ph.D.
- Brandon Kenwood
- Francis Lee, Ph.D.
- Lixia Li, Ph.D.
- Timothy Lim, Ph.D.
- Daniel Mandel, Ph.D.
- Joanne Mei, Ph.D.
- Kristina Mercer
- Gyliann Peña
- Konstantinos Petritis, Ph.D.
- Sean Scott
- Robert Vogt, Ph.D.
- Irene Williams
- Sophia Winchester
- Golriz Yazdanpanah
- Sherri Zobel

**Production:**
- Sarah Brown
- Kizzy Stewart
- Kimberly Coulter

**ASSOCIATION OF PUBLIC HEALTH LABORATORIES SILVER SPRING, MD 20910**

**President**
Ewa King, PhD

**Chairman, Newborn Screening and Genetics in Public Health Committee**
Michele Caggana, Sc.D., FACMG

**Chairman, Newborn Screening Quality Assurance Quality Control Subcommittee**
Patricia R. Hunt, B.A. and Joseph Orsini, Ph.D.

**Chairman, Newborn Screening Molecular Subcommittee**
Rachel Lee, Ph.D.

**INQUIRIES TO:**
Irene Williams, Editor • Centers for Disease Control and Prevention (CDC) • Newborn Screening Quality Assurance Program
Mailstop F-24 • 4770 Buford Highway, N.E. • Atlanta, GA 30341-3724
Phone (770) 488-4582 • NSQAPDMT@cdc.gov
E-mail: IWilliams1@cdc.gov